AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung cancer (SCLC).
AstraZeneca has announced that its monoclonal antibody, Imfinzi (durvalumab), was found to improve overall survival at interim analysis in the Phase III CASPIAN trial in 1st-line extensive-stage small cell lung cancer.
AstraZeneca has announced top-line results from the pooled cardiovascular (CV) safety analyses of its global Phase III roxadustat programme.
AstraZeneca has announced two Lancet Oncologypublications of its Phase I dose-expansion results of DS-8201 (trastuzumab deruxtecan) in HER2-positive metastatic breast and gastric cancer.
Imfinzi is the first immunotherapy to demonstrate significant overall survival benefit in unresectable, Stage III lung cancer
AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi during the Presidential Symposium of the IASLC 19th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Toronto, Canada.